Loading...
XNAS
STIM
Market cap148mUSD
Oct 08, Last price  
2.14USD
1D
-1.38%
1Q
21.59%
IPO
-91.96%
Name

Neuronetics Inc

Chart & performance

D1W1MN
XNAS:STIM chart
P/E
—
P/S
1.00
EPS
—
Div yield, %
—
Shrs. gr., 5y
28.48%
Rev. gr., 5y
24.81%
Revenues
149m
+99.17%
34,228,00040,433,00052,776,00062,656,00049,244,00055,312,00065,206,00071,348,00074,890,000149,157,000
Net income
-39m
L-10.78%
-11,234,000-16,059,000-24,097,000-29,044,000-27,453,000-31,193,000-37,159,000-30,189,000-43,708,000-38,998,000
CFO
-20m
L-34.27%
-8,541,000-11,144,000-20,591,000-30,482,000-28,390,000-27,983,000-30,739,000-32,038,000-30,997,000-20,374,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.

Key people

Brian E. Farley
Independent Chairman of the Board · since 2011
Christopher A. Thatcher
President, Chief Executive Officer, Director · since 2016
Peter L. Donato
Chief Financial Officer, Vice President · since 2017
Gregory Harper
Vice President - Product Development and Operations · since 2016
Yelena Tropsha
Vice President - Commercial Access · since 2018
Daniel Guthrie
Chief Commercial Officer · since 2018
Independent Director · since 2019
Sheryl L. Conley
Independent Director · since 2019
Independent Director · since 2017
IPO date
Jun 28, 2018
Employees
209
Domiciled in
US
Incorporated in
US
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
322 Phoenixville Pike
Malvern, PA 19355
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT